Cwm, LLC Galectin Therapeutics Inc Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Cwm, LLC holds 170 shares of GALT stock, worth $147. This represents 0.0% of its overall portfolio holdings.

Number of Shares

170

Holding current value

$147

% of portfolio

0.0%

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	BUY	$2.04 - $2.86 $346 - $486	170 New	170 $0
Q2 2019 Jul 31, 2019	BUY	$3.61 - $5.0 $2,783 - $3,855	771 Added 38.55%	2,771 $11,000
Q2 2018 Jul 31, 2018	BUY	$3.16 - $9.16 $6,320 - $18,320	2,000 New	2,000 $13,000

Others Institutions Holding GALT

# of Institutions

Shares Held

9.65M

Call Options Held

1.16M

Put Options Held

1.98M

Vanguard Group Inc Valley Forge, PA

2.13M
Shares

$1.86 Million
0.0% of portfolio
Black Rock Inc. New York, NY

1.56M
Shares

$1.36 Million
0.0% of portfolio
Advisor Group Holdings, Inc. Phoenix, AZ

1.18M
Shares

$1.03 Million
0.01% of portfolio
Geode Capital Management, LLC Boston, MA

863K
Shares

$750,411
0.0% of portfolio
Commonwealth Equity Services, LLC

483K
Shares

$420,439
0.0% of portfolio

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $51.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account